Navigation Links
PharmAthene Reports Year-End 2009 Financial and Operational Results and Provides Update On Ongoing Litigation With SIGA Technologies
Date:3/23/2010

easures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim® - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit www.PharmAthene.com.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Pr
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. PharmAthene to Provide Update on SparVax(TM) Contract Modification Suspension During Year-End 2009 Financial and Operational Results Conference Call on Tuesday March 23, 2010
2. PharmAthene to Host Year-End 2009 Earnings Conference Call and Webcast on Tuesday, March 23, 2010
3. PharmAthene to Present at the 2010 Roth Capital Markets Growth Stock Conference on Monday, March 15, 2010
4. PharmAthene Submits White Paper to BARDA for Advanced Development Funding for SparVax(TM) - Novel Recombinant Protective Antigen Anthrax Vaccine
5. PharmAthene Appoints Jeffrey W. Runge, M.D. to the Companys Board of Directors
6. PharmAthene Announces Updated Time for Conference Call to Review BARDA rPA Decision
7. PharmAthene Reports Third Quarter 2009 Financial and Operational Results
8. PharmAthene Executives Featured in Anthrax Pathogen Training Video for U.S. Department of Homeland Security
9. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
10. PharmAthene to Present at the Rodman and Renshaw Annual Global Investment Conference September 10, 2009
11. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... ... 04, 2015 , ... November Research Group, LLC, a global ... to pharmaceutical and life sciences organizations, today announced the production implementation of its ... data intake solution that enables field sales representatives, clinical research associates, and product ...
(Date:9/3/2015)... 3, 2015 /PRNewswire/ - bioLytical Laboratories Inc., a leader ... study " Sensitivity of a rapid point of care ... its affinity for HIV gp41 IgM antibodies " has ... study highlights INSTI,s ability to detect early HIV infection.  ... the 8 th annual International AIDS Society Conference, ...
(Date:9/3/2015)... ... ... If you plan to attend the 27th annual Tradeline College and University ... up for the tour of Framingham State University's newest addition to Hemenway Hall taking ... (8) chemistry teaching labs that are exclusively utilizing (49) filtered fume hoods that ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "Biochips ... to their offering. This report is ... and applications. The report starts with a description ... markets. Technologies include array comparative genomic hybridization (CGH), ...
Breaking Biology Technology:November Research Group’s PRIMO Mobile Goes Live at Allergan Japan 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 2bioLytical's INSTI HIV Test Detects gp41 specific IgM Antibodies 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2
... 28, 2012 Regado Biosciences, Inc., a privately held company ... announced that David J. Mazzo, PhD, President and CEO, will ... Annual Health Care Conference at 1:30 p.m. EST on March ... MA.  The presentation will include an overview ...
... ViroPharma Incorporated (Nasdaq: VPHM ) reported today its ... 31, 2011. In 2011, we: Achieved ... $251 million in net sales of Cinryze® (C1 esterase inhibitor ... Hydrochloride Capsules, USP); Attained non-GAAP adjusted net income of ...
... 28, 2012 Ultragenyx Pharmaceutical Inc., a biotechnology ... ultra-rare genetic disorders, today announced that the FDA ... drug designation for UX003 for the treatment of ... autosomal recessive lysosomal storage disorder characterized by a ...
Cached Biology Technology:Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 2Regado Biosciences, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston, MA 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3
(Date:8/6/2015)... Germany , August 6, 2015 ... (SMI) shows the world,s first Eye Tracking ... Epson,s Moverio BT-200 see-through head mounted display and on ... unprecedented quality and efficiency is brought to personalized visualization ... the first time, professionals and researchers can integrate gaze, ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
Breaking Biology News(10 mins):SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2
... A new study has found that the allergenicity of ... fermentation process. Researchers from North Carolina A&T University report ... the American Society for Microbiology. , "Due to the ... cookies, snacks and even soups there is a need ...
... viral-based therapies for cancer , Researchers at Columbia University ... to develop the next generation of effective viral-based therapies ... genetically engineered viruses studied in mice, published today in ... National Academy of Sciences (PNAS), bring us significantly closer ...
... have had an accelerated childhood compared to that of modern ... by researchers from Ohio State University and the University of ... tooth growth present in the Neanderthal fossils they examined was ... , And since the rate of tooth growth has ...
Cached Biology News:Columbia scientists develop cancer terminator viruses 2Columbia scientists develop cancer terminator viruses 3Neanderthal teeth grew no faster than comparable modern humans' 2Neanderthal teeth grew no faster than comparable modern humans' 3
... The DNA Engine Tetrad thermal cycler ... the pioneering PTC-200 DNA Engine cycler. ... the capacity with a footprint only ... throughput for laboratories that run massive ...
The sealed ice cooling unit is used to absorb heat that is generated during transfers performed in the Criterion blotter....
The SVT3-2 diverter valve is a 3-port, 2-position valve for use with the BioLogic DuoFlow system....
... PROTEAN II xi multi-cell is for 2-D separations. ... cooling capabilities. The PROTEAN II xi multi-cell can ... type of glass plates, and cooling system. The ... to the PROTEAN II XL multi-cell for a ...
Biology Products: